<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical treatments for blepharokeratoconjunctivitis in children - O'Gallagher, M - 2017 | Cochrane Library</title> <meta content="Topical treatments for blepharokeratoconjunctivitis in children - O'Gallagher, M - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011965.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical treatments for blepharokeratoconjunctivitis in children - O'Gallagher, M - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011965.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011965.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical treatments for blepharokeratoconjunctivitis in children" name="citation_title"/> <meta content="Michael O'Gallagher" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Catey Bunce" name="citation_author"/> <meta content="Kings College London" name="citation_author_institution"/> <meta content="Melanie Hingorani" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Frank Larkin" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Stephen Tuft" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Annegret Dahlmann‐Noor" name="citation_author"/> <meta content="NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology" name="citation_author_institution"/> <meta content="annegret.dahlmann-noor@moorfields.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD011965.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/02/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011965.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011965.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011965.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Anti‐Allergic Agents [*administration &amp; dosage, adverse effects]; Anti‐Bacterial Agents [*administration &amp; dosage, adverse effects]; Blepharitis [*drug therapy]; Conjunctiva [microbiology]; Eyelids [microbiology]; Keratoconjunctivitis [*drug therapy]; Loteprednol Etabonate [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Tobramycin [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011965.pub2&amp;doi=10.1002/14651858.CD011965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011965\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011965\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011965.pub2",title:"Topical treatments for blepharokeratoconjunctivitis in children",firstPublishedDate:"Feb 7, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011965.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011965.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011965.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011965.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011965.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011965.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011965.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011965.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011965.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011965.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3224 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011965.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0072"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/appendices#CD011965-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical treatments for blepharokeratoconjunctivitis in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0002">Michael O'Gallagher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0003">Catey Bunce</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0004">Melanie Hingorani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0005">Frank Larkin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0006">Stephen Tuft</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information#CD011965-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Annegret Dahlmann‐Noor</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information/en#CD011965-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 February 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011965.pub2">https://doi.org/10.1002/14651858.CD011965.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011965-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011965-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011965-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011965-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011965-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011965-abs-0001" lang="en"> <section id="CD011965-sec-0001"> <h3 class="title" id="CD011965-sec-0001">Background</h3> <p>Blepharokeratoconjunctivitis (BKC) is a type of inflammation of the surface of the eye and eyelids that involves changes of the eyelids, dysfunction of the meibomian glands, and inflammation of the conjunctiva and cornea. Chronic inflammation of the cornea can lead to scarring, vascularisation and opacity. BKC in children can cause significant symptoms including irritation, watering, photophobia and loss of vision from corneal opacity, refractive error or amblyopia. </p> <p>Treatment of BKC is directed towards modification of meibomian gland disease and the bacterial flora of lid margin and conjunctiva, and control of ocular surface inflammation. Although both topical and systemic treatments are used to treat people with BKC, this Cochrane review focuses on topical treatments. </p> </section> <section id="CD011965-sec-0002"> <h3 class="title" id="CD011965-sec-0002">Objectives</h3> <p>To assess and compare data on the efficacy and safety of topical treatments (including antibiotics, steroids, immunosuppressants and lubricants), alone or in combination, for BKC in children from birth to 16 years. </p> </section> <section id="CD011965-sec-0003"> <h3 class="title" id="CD011965-sec-0003">Search methods</h3> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE ( January 1946 to 11 July 2016), Embase (January 1980 to 11 July 2016), the ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 11 July 2016. We searched the reference lists of identified reports and the Science Citation Index to identify any additional reports of studies that met the inclusion criteria. </p> </section> <section id="CD011965-sec-0004"> <h3 class="title" id="CD011965-sec-0004">Selection criteria</h3> <p>We searched for randomised controlled trials that involved topical treatments in children up to 16 years of age with a clinical diagnosis of BKC. We planned to include studies that evaluated a single topical medication versus placebo, a combination of treatments versus placebo, and those that compared two or multiple active treatments. We planned to include studies in which participants received additional treatments, such as oral antibiotics, oral anti‐inflammatories, warm lid compresses and lid margin cleaning. </p> </section> <section id="CD011965-sec-0005"> <h3 class="title" id="CD011965-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the results of the literature search (titles and abstracts) to identify studies that met the inclusion criteria of the review and applied standards as expected for Cochrane reviews. We graded the certainty of the evidence using GRADE. </p> </section> <section id="CD011965-sec-0006"> <h3 class="title" id="CD011965-sec-0006">Main results</h3> <p>We included one study from the USA that met the inclusion criteria. In the study, 137 children aged zero to six years old with blepharoconjunctivitis were randomised to treatment in one of four trial arms (loteprednol etabonate/tobramycin combination, loteprednol etabonate alone, tobramycin alone or placebo) for 15 days, with assessments on days 1, 3, 7 and 15. We judged the study to be at high risk of attrition bias and bias due to selective outcome reporting. The study did not report the number of children with improvement in symptoms nor with total or partial success as measured by changes in clinical symptoms. </p> <p>All children showed a reduction in blepharoconjunctivitis grade score, but there was no evidence of important differences between groups. Visual acuity was not fully reported but the authors stated that there was no change in visual acuity in any of the treatment groups. The study reported ocular and non ocular adverse events but was underpowered to detect differences between the groups. Ocular adverse events were as follows: loteprednol/tobramycin 1/34 (eye pain); loteprednol 4/35 (eye pain, conjunctivitis, eye discharge, eye inflammation); tobramycin 0/34; placebo (vehicle) 0/34. The evidence was limited for all these outcomes and we judged it to be very low certainty. </p> <p>There was no information on clinical signs (aside from grade score), disease progression or quality of life. </p> </section> <section id="CD011965-sec-0007"> <h3 class="title" id="CD011965-sec-0007">Authors' conclusions</h3> <p>There is no high‐quality evidence of the safety and efficacy of topical treatments for BKC, which resulted in uncertainty about the indications and effectiveness of topical treatment. Clinical trials are required to test efficacy and safety of current and any future treatments. Outcome measures need to be developed which can capture both objective clinical and patient‐reported aspects of the condition and treatments. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011965-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011965-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011965-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011965-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011965-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011965-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011965-abs-0003" lang="en"> <h3>Topical treatment for blepharokeratoconjunctivitis (BKC) in children</h3> <p><b>What is the aim of this review?</b> <br/> The aim of this Cochrane review was to find out if topical treatment (by eye drops or ointments) for BKC in children improves symptoms and is safe. Cochrane researchers collected and analysed all relevant studies to answer this question and included one study in this review. </p> <p><b>Key messages</b> <br/> There is no good evidence as to the benefits and harms of topical treatments for BKC in children. </p> <p><b>What was studied in the review?</b> <br/> When the surface of the eye and eyelids becomes inflamed this is known as blepharokeratoconjunctivitis or BKC. This can cause watery, itchy, red eyes that are painful in bright light. Occasionally it can lead to scarring at the front of the eye and result in loss of vision. It is a quite common reason for children attending for eye care. Antibiotics, steroids and lubricants have been considered as possible treatments for this condition and can be given as eye drops or ointments. </p> <p><b>What are the main results of the review?</b> <br/> Cochrane researchers found one study that looked at the effects of a combination of steroids and antibiotics in treatment of BKC in children. The study did not report the effects of this treatment clearly and was too small to provide a good assessment of safety. </p> <p><b>How up‐to‐date is this review?</b> <br/> The Cochrane researchers searched for studies that had been published up to 11 July 2016. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011965-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011965-sec-0090"></div> <h3 class="title" id="CD011965-sec-0091">Implications for practice</h3> <section id="CD011965-sec-0091"> <p>In the absence of high‐quality evidence about the efficacy and safety of different treatment regimes, there is uncertainty about indications and effectiveness of systemic treatment. Most published work consists of case series, without control groups. Outcome measures vary greatly, which makes comparisons between studies difficult. </p> </section> <h3 class="title" id="CD011965-sec-0092">Implications for research</h3> <section id="CD011965-sec-0092"> <p>Clinical trials are required to test efficacy and safety of current and any future treatments such as topical antibiotics, topical steroids and other immunosuppressants, lubricants or combinations thereof. There is a need for standardised outcome measures to be developed, aiming to capture both objective clinical and patient‐reported aspects of the condition and treatments. </p> <p>This review has shown a lack of high quality RCTs that evaluate topical treatments in BKC in children. There is a lack of consistency in the literature on terminology, disease definitions and outcome reporting. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011965-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011965-sec-0022"></div> <div class="table" id="CD011965-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical treatments compared with control for blepharokeratoconjunctivitis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with blepharokeratoconjunctivitis </p> <p><b>Settings:</b> eye clinic </p> <p><b>Intervention:</b> topical treatments (antibiotics and/or steroids) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo (vehicle)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>topical treatments (antibiotics/steroids)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms, reported by the child or by their parents/carers, preferably measured by a validated tool, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on changes in grade of blepharoconjunctivitis measured between baseline and 2 weeks did not suggest any important differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of clinical signs of ocular surface inflammation ('partial success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on changes in grade of blepharoconjunctivitis measured between baseline and 2 weeks did not suggest any important differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in best corrected visual acuity in affected eye(s) in logMAR measured with an ETDRS chart at 4 m, or, in younger children, with a Keeler crowded logMAR chart at 3 m, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data in a form that could not be extracted; not statistically significant differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of medication, at any time during treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Ocular adverse events</p> <p> <ul id="CD011965-list-0001"> <li> <p>Loteprednol/tobramycin 1/34 (eye pain)</p> </li> <li> <p>Loteprednol 4/35 (eye pain, conjunctivitis, eye discharge, eye inflammation)</p> </li> <li> <p>Tobramycin 0/34</p> </li> <li> <p>Vehicle 0/34</p> </li> </ul> </p> <p>Non‐ocular adverse events</p> <p> <ul id="CD011965-list-0002"> <li> <p>Loteprednol/tobramycin 3 in 2/34 people (gastroenteritis, pyrexia, bronchiolitis)</p> </li> <li> <p>Loteprednol 9 in 6/35 people (ear infection, lip swelling, vomiting, URI, varicella, cough, phyarngolaryngeal pain, rash) </p> </li> <li> <p>Tobramycin 9 in 6/34 people (ear infection, otitis media acute, diarrhea, pyrexia, bronchioltis, URI, nasophayngitis, respirator distress, dermatitis (diaper) ) </p> </li> <li> <p>Vehicle 7 in 5/33 people (ear pain, pyrexia, urticaria, bronchioloitis, URI, tonsilitis, dehydration) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Some data on blepharoconjunctivitis grade reported on trials registry but we were unable to estimate a measure of effect for this outcome. </p> <p>2 Data were not fully reported and we were unable to estimate a measure of effect for change in visual acuity. </p> <p>3 Very low certainty due to very low numbers of events.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011965-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011965-sec-0023"></div> <p>This Cochrane review is one of two reviews on blepharokeratoconjunctivitis (BKC). We used our previous review on systemic treatments for BKC as the template for this review (<a href="./references#CD011965-bbs2-0052" title="O'GallagherM , BantekaM , BunceC , LarkinF , TuftS , Dahlmann‐NoorA . Systemic treatment for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011750.pub2] ">O'Gallagher 2016</a>), and some of the text is similar. </p> <section id="CD011965-sec-0024"> <h3 class="title" id="CD011965-sec-0024">Description of the condition</h3> <p>BKC is a type of inflammation of the surface of the eye and eyelids. The diagnosis is clinical and based on changes of the lid margin (telangiectasia, thickening, scarring), meibomian gland dysfunction (MGD), redness of the eye (conjunctival hyperaemia), conjunctival chemosis and inflammation of the cornea (punctate epithelial keratitis, corneal opacities, ulceration, thinning, vascularisation and scarring) (<a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). Inflammation of the ocular surface causes symptoms such as watering, itching, foreign body sensation, burning sensation, eye rubbing and sensitivity to light (photophobia) (<a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). </p> <p>The incidence and prevalence of BKC in children are unknown. In paediatric eye clinics, BKC is a common diagnosis and is estimated to be the reason for referral in 12% to 15% of cases (<a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>; <a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a>; <a href="./references#CD011965-bbs2-0033" title="HammersmithKM . Blepharokeratoconjunctivitis in children. Current Opinion in Ophthalmology2015;26(4):301‐5. ">Hammersmith 2015</a>). The gender distribution differs between published case series; there does not appear to be a definite male or female predilection. Children of South Asian descent may be more frequently affected. In a UK case series of 44 children, 50% were of Indian or Sri Lankan descent, 45.5% white and 4.5% of Middle Eastern origin (<a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). In another UK case series of 27 children, 63% were white, 30% of Indian or Pakistani origin, 4% of Middle Eastern and 4% of Chinese origin (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). The age of onset is early childhood, and case series report a mean age of onset of 3.2 to 4.5 years, with a range of five months to 13 years (<a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a>; <a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). The young age of onset means that children are at risk of developing secondary amblyopia, which is a loss of vision due to the brain not learning how to process high‐resolution visual information. Indeed, one paediatric case series recorded reduced visual acuity despite treatment in 70% of affected eyes with a rate of amblyopia of 56% (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>); all included children in this report from a tertiary referral centre had severe disease with corneal involvement in at least one eye, which may have led to selection bias. Refractive error (both spherical and cylindrical) is common (<a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). A particularly severe phenotype with prolonged duration of the condition into adulthood, a systemic association with rosacea and a high risk of corneal complications, such as thinning, vascularisation and perforation, have been observed in a proportion of white patients (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>). Whilst this review is concerned with the medical management of BKC, surgical interventions are occasionally indicated, such as the injection of monoclonal antibodies that target molecules of the vascular epithelial growth factor pathway in corneal vascularisation (<a href="./references#CD011965-bbs2-0013" title="ChangJH , GargNK , LundeE , HanKY , JainS , AzarDT . Corneal neovascularization: an anti‐VEGF therapy review. Survey of Ophthalmology2012;57(5):415‐29. ">Chang 2012</a>; <a href="./references#CD011965-bbs2-0022" title="ElbazU , MireskandariK , ShenC , AliA . Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children. Cornea2015;34(7):773‐7. ">Elbaz 2015</a>; <a href="./references#CD011965-bbs2-0068" title="StevensonD , TauberJ , ReisBL . Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate‐to‐severe dry eye disease: a dose‐ranging, randomized trial. Ophthalmology2000;107(5):967‐74. ">Stevenson 2000</a>), gluing or corneal transplantation for corneal perforation, and corneal transplantation for severe scarring; the latter being associated with a high risk of rejection because of corneal vascularisation (<a href="./references#CD011965-bbs2-0045" title="LindsleyK , MatsumuraS , HatefE , AkpekEK . Interventions for chronic blepharitis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD005556.pub2] ">Lindsley 2012</a>). </p> <p>Early features of BKC are lid margin disease and chalazia (cysts within the eyelid) (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). Qualitative and quantitative tear film lipid deficiency and the activation of inflammatory pathways may be underlying factors which lead to the conjunctival and corneal signs and symptoms that distinguish BKC from blepharitis (<a href="./references#CD011965-bbs2-0026" title="FoulksGN , BronAJ . Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface2003;1(3):107‐26. ">Foulks 2003</a>; <a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0070" title="SuzukiT , TeramukaiS , KinoshitaS . Meibomian glands and ocular surface inflammation. The Ocular Surface2015;13(2):133‐49. ">Suzuki 2015</a>). BKC is a chronic condition and early intervention may help prevent severe corneal disease with loss of vision (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). </p> <section id="CD011965-sec-0025"> <h4 class="title">Meibomian gland dysfunction</h4> <p>The meibomian glands, located in the eyelids, secrete a layer of lipids and proteins that protect the tear film against evaporation. Dysfunction of these glands can result in a sensation of dryness or grittiness. Many suggestions about the mechanisms underlying MGD and its management have been made, mainly in adults. We have provided a summary of the recent literature in <a href="./appendices#CD011965-sec-0095">Appendix 1</a>. </p> </section> <section id="CD011965-sec-0026"> <h4 class="title">Bacterial flora on lid margin and conjunctiva</h4> <p>Bacteria secrete enzymes, such as lipases, that may further destabilise the tear film (<a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a>; <a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>; <a href="./references#CD011965-bbs2-0051" title="NicholsKK , FoulksGN , BronAJ , GlasgowBJ , DogruM , TsuhotaK , et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science2011;52(4):1922‐9. ">Nichols 2011</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). </p> <p>Conjunctival cultures from healthy children frequently grow staphylococcal species pluralis (spp.) (42%) and diphtheroids (30%) and, occasionally, streptococcal spp. (13%), <i>Propionibacterium acnes</i> (11%) and <i>Corynebacterium</i> spp. (2%) (<a href="./references#CD011965-bbs2-0065" title="SingerTR , IsenbergSJ , AptL . Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. British Journal of Ophthalmology1988;72(6):448‐51. ">Singer 1988</a>). In children with BKC, a case series of four children reported low numbers of coagulase‐negative staphylococci in lid cultures of three children and low numbers of <i>P. acnes</i> in one child (<a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a>). Another case series of 44 children with BKC reported culture‐positive lid margin and conjunctival swabs in 15 (34.1%), and of these, 12 showed a moderate or heavy growth of <i>Staphylococcus aureus,</i> one <i>S. epidermidis</i> and two mixed <i>S. aureus</i> /<i>S. epidermidis</i> (<a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). A large case series from a centre in India found positive cultures in 52 of 290 children with BKC (17.9%), of which 34/52 grew <i>S. aureus,</i> 13/52 grew <i>P. acnes</i> and 5/52 grew both (<a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>). </p> </section> <section id="CD011965-sec-0027"> <h4 class="title">Diagnostic tests</h4> <p>Diagnosis of BKC is based on symptoms and clinical signs, as described above. Lid margin and conjunctival swabs for bacterial culture are not performed routinely in clinical practice. Similarly, lid margin changes are not routinely quantified. However, grading and scoring systems of clinical signs, adapted from systems used in adults, have been proposed (<a href="./references#CD011965-bbs2-0051" title="NicholsKK , FoulksGN , BronAJ , GlasgowBJ , DogruM , TsuhotaK , et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science2011;52(4):1922‐9. ">Nichols 2011</a>). </p> <p>The examination of children is often limited by patient co‐operation, particularly when ocular surface inflammation is severe, and photophobia and discomfort are intense. However, some of the subgroups used in the MGD staging system have been used to develop a staging system for childhood BKC. Viswalingam and colleagues introduced a classification for BKC severity based on bulbar and tarsal conjunctival signs (hyperaemia, infiltration, obscuration of tarsal conjunctival vessels, and the presence of papillae and follicles) and the extent of corneal involvement in degrees at the limbus (less than 120°, 180° to 240°, 240° to 360) (<a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). This system was expanded to include elements of the conjunctival active inflammation score (<a href="./references#CD011965-bbs2-0023" title="ElderMJ , BernauerW . Monitoring of activity and progression in cicatrising conjunctivitis. Developments in Ophthalmology1997;28:111‐22. ">Elder 1997</a>), the Chronic Stevens Johnson Syndrome/Toxic Epidermal Necrolysis score (<a href="./references#CD011965-bbs2-0066" title="SotozonoC , AngLP , KoizumiN , HigashiharaH , UetaM , InatomiT , et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens‐Johnson syndrome. Ophthalmology2007;114(7):1294‐302. ">Sotozono 2007</a>), and the abbreviated MGD grading system (<a href="./references#CD011965-bbs2-0011" title="BronAJ , EvansVE , SmithJA . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea2003;22(7):640‐50. ">Bron 2003</a>; <a href="./references#CD011965-bbs2-0026" title="FoulksGN , BronAJ . Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface2003;1(3):107‐26. ">Foulks 2003</a>). The resulting grading system has four grades (none, mild, moderate, severe), each with separate grading for disease activity (A) and damage (D) (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>). Activity scoring is based on conjunctival hyperaemia/oedema, corneal vascularisation (three clock hours or less, more than three clock hours, peripheral/to pupil margin/into central zone), and conjunctival or corneal ulceration or corneal perforation. Damage scoring is based on lid distortion, subconjunctival fibrosis (fornix shortening), the presence and extent of established vessels/fibrovascular pannus and peripheral/central corneal thinning (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>). The latest addition to this system includes the Oxford scoring system of corneal staining (<a href="./references#CD011965-bbs2-0011" title="BronAJ , EvansVE , SmithJA . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea2003;22(7):640‐50. ">Bron 2003</a>; <a href="./references#CD011965-bbs2-0031" title="HamadaS , NischalK , EvansJ . The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):e16. ">Hamada 2013</a>). This scoring system can be used to evaluate treatment efficacy, such as: complete success, signified by a reduction in activity scores from any grade to A0 ('no activity'); partial success, signified by a reduction in activity scoring not reaching grade A0; and treatment failure, signified by no change in or a worsening of activity scoring (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>, <a href="./references#CD011965-bbs2-0031" title="HamadaS , NischalK , EvansJ . The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):e16. ">Hamada 2013</a>). </p> <p>A functional measure of activity and damage is visual acuity; this may also indicate the presence of secondary amblyopia (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). </p> </section> </section> <section id="CD011965-sec-0028"> <h3 class="title" id="CD011965-sec-0028">Description of the intervention</h3> <p>Akin to the treatment of adult MGD and blepharitis, the treatment of childhood BKC targets the obstruction of meibomian gland openings (melting, expression and removal of meibomian gland secretions and debris from the lid margin by daily warm lid compresses and lid margin cleaning), the altered bacterial flora of lid margin and conjunctiva (topical and systemic antibiotics), and ocular surface inflammation (topical immunosuppressants and topical/systemic antibiotics inhibiting bacterial lipases, topical lubricants diluting inflammatory mediators in the tear film and compensating for tear film deficiency). Dietary modifications, particularly an increased intake in essential fatty acids (EFAs), may also be of benefit (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). Rarely, systemic immunosuppression with prednisolone, azathioprine or mycophenolate mofetil may be required to treat sight‐threatening corneal involvement (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>). </p> <p>This review focuses on topical treatments.</p> </section> <section id="CD011965-sec-0029"> <h3 class="title" id="CD011965-sec-0029">How the intervention might work</h3> <section id="CD011965-sec-0030"> <h4 class="title">Topical antibiotics</h4> <p>Topical antibiotics are used in BKC for both their antibiotic and anti‐inflammatory effects. <i>S. aureus</i> and <i>S. epidermidis</i> are common organisms cultured from conjunctival and lid swabs in BKC and topical antibiotics with appropriate spectrum of activity are used (<a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). Ointments are often used to coat the lashes (<a href="./references#CD011965-bbs2-0056" title="RaskinEM , SpeakerMG , LaibsonPR . Blepharitis. Infectious Disease Clinics of North America1992;6(4):777‐87. ">Raskin 1992</a>). Topical antibiotics may be used alone in mild disease (<a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>), or more commonly in conjunction with systemic antibiotics in more severe disease or to aid compliance in children (<a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>; <a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). </p> <section id="CD011965-sec-0031"> <h5 class="title">Macrolides</h5> <p>Erythromycin is the most commonly‐used systemic antibiotic in childhood BKC (<a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a>; <a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0048" title="MeislerDM , RaizmanMB , TraboulsiEI . Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS2000;4(6):379‐80. ">Meisler 2000</a>), and its use has also been reported topically (<a href="./references#CD011965-bbs2-0048" title="MeislerDM , RaizmanMB , TraboulsiEI . Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS2000;4(6):379‐80. ">Meisler 2000</a>; <a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). Newer macrolide antibiotics, such as azithromycin, are also available. Topical azithromycin use has been described in childhood BKC with the reported advantage of a long half‐life due to tissue accumulation of the drug (<a href="./references#CD011965-bbs2-0020" title="DoanS , GabisonE , ChiambarettaF , TouatiM , CochereauI . Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. Journal of Ophthalmic Inflammation and Infection2013;3:38. ">Doan 2013</a>). Macrolide antibiotics have both antibacterial and anti‐inflammatory properties. They inhibit bacterial protein synthesis by binding to the 50S subunit of bacterial 70S ribosomes (<a href="./references#CD011965-bbs2-0040" title="KleinJO . History of macrolide use in pediatrics. Pediatric Infectious Disease Journal1997;16(4):427‐31. ">Klein 1997</a>). The effect can be bactericidal or bacteriostatic, depending on the bacterial species, drug concentration, growth phase of the organism and inoculum size (<a href="./references#CD011965-bbs2-0040" title="KleinJO . History of macrolide use in pediatrics. Pediatric Infectious Disease Journal1997;16(4):427‐31. ">Klein 1997</a>). In vitro, macrolide antibiotics reduce the release of proinflammatory cytokines, particularly IL‐1beta, ‐6, ‐8 and ‐12, tumour necrosis factor‐alpha (TNF‐alpha), and matrix metalloproteinases (MMPs) ‐1, ‐3 and ‐9, and affect neurophil chemotaxis and phagocytosis (<a href="./references#CD011965-bbs2-0027" title="GeerlingG , TauberJ , BaudouinC , GotoE , MatsumotoY , O'BrienT , et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2011;52(4):2050‐64. ">Geerling 2011</a>; <a href="./references#CD011965-bbs2-0044" title="LiDQ , ZhouN , ZhangL , MaP , PflugfelderSC . Suppressive effects of azithromycin on zymosan‐induced production of proinflammatory mediators by human corneal epithelial cells. Investigative Ophthalmology and Visual Science2010;51(11):5623‐9. ">Li 2010</a>; <a href="./references#CD011965-bbs2-0049" title="MurphyBS , SundareshanV , CoryTJ , HayesD , AnsteadMI , FeolaDJ . Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy2008;61(3):554‐60. ">Murphy 2008</a>). In an animal model of corneal inflammation, azithromycin reduced leucocyte migration into the cornea and decreased mRNA expression levels of IL‐1beta, TNF‐alpha and intercellular adhesion molecule (ICAM)‐1 (<a href="./references#CD011965-bbs2-0063" title="SadraiZ , HajrasoulihaAR , ChauhanS , SabanDR , DastjerdiMH , DanaR . Effect of topical azithromycin on corneal innate immune responses. Investigative Ophthalmology and Visual Science2011;52(5):2525‐31. ">Sadrai 2011</a>). The risk of adverse effects is low, and no adverse events have been reported with topical use. </p> </section> <section id="CD011965-sec-0032"> <h5 class="title">Chloramphenicol</h5> <p>Chloramphenicol is an antibiotic effective mainly against Gram‐positive bacteria; it is bacteriostatic through the inhibition of protein synthesis (<a href="./references#CD011965-bbs2-0059" title="RobertPY , AdenisJP . Comparative review of topical ophthalmic antibacterial preparations. Drugs2001;61(2):175‐85. ">Robert 2001</a>). It has been shown to be effective against 94% of bacterial isolates in blepharitis and conjunctivitis (<a href="./references#CD011965-bbs2-0024" title="EverettSL , KowalskiRP , KarenchakLM , LandsittelD , DayR , GordonYJ . An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and blepharitis to newer and established topical antibiotics. Cornea1995;14(4):382‐7. ">Everett 1995</a>). Its use has been described in BKC in children (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>; <a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). No adverse effects were reported with its use topically in children for BKC in small case series (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). </p> </section> <section id="CD011965-sec-0033"> <h5 class="title">Other topical antibiotics</h5> <p>Other topical antibiotics used in BKC in children include fusidic acid (<a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>), gentamicin (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>), and ciprofloxacin (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). No side effects have been reported apart from mild punctate epithelial erosions in one child receiving topical ciprofloxacin (<a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>). </p> </section> </section> <section id="CD011965-sec-0034"> <h4 class="title">Immunosuppressants and ‐modulators</h4> <section id="CD011965-sec-0035"> <h5 class="title">Topical corticosteroids</h5> <p>Glucocorticoids have a potent anti‐inflammatory effect; they bind to cytoplasmic glucocorticoid steroid receptors and translocate to the nucleus of the cell, and induce an increase in the transcription of proteins that inhibit the production of inflammatory mediators, e.g. lipocortin. Corticosteroids also inhibit the transcription of proinflammatory cytokines. Adverse effects of topical corticosteroid therapy include a rise in intraocular pressure, with subsequent damage of the retinal ganglion cell axons (glaucoma), opacification of the crystalline lens (cataract), increased susceptibility of the cornea to infection (bacterial/herpetic keratitis, with risk of corneal scar or perforation), and, as reported in isolated cases only, adrenal suppression, Cushing syndrome and growth retardation (<a href="./references#CD011965-bbs2-0007" title="AfandiB , ToumehMS , SaadiHF . Cushing's syndrome caused by unsupervised use of ocular glucocorticoids. Endocrine Practice2003;9(6):526‐9. ">Afandi 2003</a>; <a href="./references#CD011965-bbs2-0014" title="ChiangMY , SarkarM , KoppensJM , MillesJ , ShahP . Exogenous Cushing's syndrome and topical ocular steroids. Eye2006;20(6):725‐7. ">Chiang 2006</a>; <a href="./references#CD011965-bbs2-0041" title="KrupinT , MandellAI , PodosSM , BeckerB . Topical corticosteroid therapy and pituitary‐adrenal function. Archives of Ophthalmology1976;94(6):919‐20. ">Krupin 1976</a>; <a href="./references#CD011965-bbs2-0067" title="SteelmanJ , KappyM . Adrenal suppression and growth retardation from ocular corticosteroids. Journal of Pediatric Ophthalmology and Strabismus2001;38(3):177‐8. ">Steelman 2001</a>; <a href="./references#CD011965-bbs2-0077" title="WolthersOD . Growth suppression caused by corticosteroid eye drops. Journal of Pediatric Endocrinology and Metabolism2011;24(5‐6):393‐4. ">Wolthers 2011</a>). Frequently used in BKC are — in decreasing order of potency — topical dexamethasone, prednisolone, fluorometholone (<a href="./references#CD011965-bbs2-0003" title="ChenM , GongL , SunX , GuY , HeX , QuJ , et al. A multicenter, randomized, parallel‐group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion2012;28(3):385‐94. ">Chen 2012</a>; <a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0004" title="HosseiniK , HutchesonJ , LindstromRL . A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clinical Ophthalmology2013;7:2225‐34. ">Hosseini 2013</a>; <a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a>; <a href="./references#CD011965-bbs2-0047" title="MehtaJS , SagooMS , TuftSJ . Subconjunctival crystals in paediatric blepharokeratoconjunctivitis. Acta Ophthalmologica Scandinavica2006;84(4):557‐8. ">Mehta 2006</a>; <a href="./references#CD011965-bbs2-0074" title="TorkildsenGL , CockrumP , MeierE , HammondsWM , SilversteinB , SilversteinS . Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Current Medical Research and Opinion2011;27(1):171‐8. ">Torkildsen 2011</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>), and, more recently, a topical corticosteroid with reported reduced risk of adverse events resulting from penetration into the anterior chamber, loteprednol (<a href="./references#CD011965-bbs2-0003" title="ChenM , GongL , SunX , GuY , HeX , QuJ , et al. A multicenter, randomized, parallel‐group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion2012;28(3):385‐94. ">Chen 2012</a>; <a href="./references#CD011965-bbs2-0016" title="ComstockTL , HollandEJ . Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opinion on Pharmacotherapy2010;11(5):843‐52. ">Comstock 2010</a>;<a href="./references#CD011965-bbs2-0017" title="ComstockTL , DecoryHH . Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. International Journal of Inflammation2012;2012:789623. [DOI: 10.1155/2012/789623] ">Comstock 2012b</a>; <a href="./references#CD011965-bbs2-0006" title="WhiteEM , MacyJI , BatemanKM , ComstockTL . Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Current Medical Research and Opinion2008;24(1):287‐96. ">White 2008</a>). In isolated cases, long‐acting corticosteroids have also been administered as injection into the episcleral space under Tenon's layer (<a href="./references#CD011965-bbs2-0010" title="BondalapatiS , CabreraMT . Sub‐tenon triamcinolone acetonide injections for topical medication intolerance in chronic blepharokeratoconjunctivitis. Cornea2014;33(9):999‐1001. ">Bondalapati 2014</a>). </p> </section> <section id="CD011965-sec-0036"> <h5 class="title">Immunomodulators</h5> <p>Calcineurin inhibitors, ciclosporin A (CSA), tacrolimus (FK506) and pimecrolimus, are immunomodulators that specifically inhibit T lymphocyte proliferation by inhibiting interleukin 2 expression by T helper cells (<a href="./references#CD011965-bbs2-0039" title="KacmazRO , KempenJH , NewcombC , DanielE , GangaputraS , NussenblattRB , et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology2010;117(3):576‐84. ">Kacmaz 2010</a>; <a href="./references#CD011965-bbs2-0071" title="TatlipinarS , AkpekEK . Topical ciclosporin in the treatment of ocular surface disorders. British Journal of Ophthalmology2005;89(10):1363‐7. ">Tatlipinar 2005</a>). </p> <section id="CD011965-sec-0037"> <h6 class="title">Ciclosporin A (CSA)</h6> <p>CSA has been used to reduce the need for topical steroids in the treatment of atopic keratoconjunctivitis; no serious adverse events were noted (<a href="./references#CD011965-bbs2-0071" title="TatlipinarS , AkpekEK . Topical ciclosporin in the treatment of ocular surface disorders. British Journal of Ophthalmology2005;89(10):1363‐7. ">Tatlipinar 2005</a>). In MGD, CSA used at a low concentration of 0.05% can reduce meibomian gland inclusions, tear film changes and signs and symptoms of corneal dryness by reducing meibomian gland inflammation and by modulating immune cell populations in the conjunctiva and lacrimal gland (<a href="./references#CD011965-bbs2-0053" title="PerryHD , Doshi‐CarnevaleS , DonnenfeldED , SolomonR , BiserSA , BloomAH . Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea2006;25(2):171‐5. ">Perry 2006</a>; <a href="./references#CD011965-bbs2-0054" title="PrabhasawatP , TesavibulN , MahawongW . A randomized double‐masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea2012;31(12):1386‐93. ">Prabhasawat 2012</a>; <a href="./references#CD011965-bbs2-0055" title="QiaoJ , YanX . Emerging treatment options for meibomian gland dysfunction. Clinical Ophthalmology2013;7:1797‐803. ">Qiao 2013</a>; <a href="./references#CD011965-bbs2-0061" title="RubinM , RaoSN . Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. Journal of Ocular Pharmacology and Therapeutics2006;22(1):47‐53. ">Rubin 2006</a>; <a href="./references#CD011965-bbs2-0064" title="SchechterBA , KatzRS , FriedmanLS . Efficacy of topical cyclosporine for the treatment of ocular rosacea. Advances in Therapy2009;26(6):651‐9. ">Schechter 2009</a>; <a href="./references#CD011965-bbs2-0068" title="StevensonD , TauberJ , ReisBL . Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate‐to‐severe dry eye disease: a dose‐ranging, randomized trial. Ophthalmology2000;107(5):967‐74. ">Stevenson 2000</a>). CSA may have advantages over topical steroids, as it does not induce profound suppression of the host immune response (<a href="./references#CD011965-bbs2-0042" title="KunertKS , TisdaleAS , SternME , SmithJA , GipsonIK . Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Archives of Ophthalmology2000;118(11):1489‐96. ">Kunert 2000</a>). </p> <p>In BKC the use of CSA has been described at concentrations of 2% as a rescue medication when topical azithromycin failed (<a href="./references#CD011965-bbs2-0019" title="DoanS , GabisonEE , Nghiem‐BuffetS , AbitbolO , GatinelD , Hoang‐XuanT . Long‐term visual outcome of childhood blepharokeratoconjunctivitis. American Journal of Ophthalmology2007;143(3):528‐9. ">Doan 2007</a>), and at 0.5% as primary treatment (<a href="./references#CD011965-bbs2-0036" title="IsmailAS , TaharinR , EmbongZ . Topical cyclosporin as an alternative treatment for vision threatening blepharokeratoconjunctivitis: a case report. International Medical Case Reports Journal2012;5:33‐7. ">Ismail 2012</a>), with successful control of inflammation and regression of corneal vascularisation within days, as well as at a concentration of 0.05% or 1% as an adjunct to other topical and systemic medication (<a href="./references#CD011965-bbs2-0009" title="Auw‐HädrichC , ReinhardT . Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe2009;106(7):635‐8. ">Auw‐Hädrich 2009</a>; <a href="./references#CD011965-bbs2-0015" title="ChoiDS , DjalilianA . Oral azithromycin combined with topical anti‐inflammatory agents in the treatment of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):112‐3. ">Choi 2013</a>). </p> </section> <section id="CD011965-sec-0038"> <h6 class="title">Tacrolimus</h6> <p>The successful use of tacrolimus has been described in two cases of BKC (<a href="./references#CD011965-bbs2-0038" title="JosephMA , KaufmanHE , InslerM . Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea2005;24(4):417‐20. ">Joseph 2005</a>). </p> <p>To date, no study has described the use of pimecrolimus in BKC.</p> </section> </section> </section> <section id="CD011965-sec-0039"> <h4 class="title">Lubricants</h4> <p>Lubricants are used by some in BKC in children in order to address the evaporative dry eye that one study reported to have resulted from meibomian gland disease (<a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). Lubricants are thought to reduce hyperosmolarity of the tears, reduce friction between the tarsal conjunctiva and the ocular surface, improve spreading of the lipid layer of the tear film, and dilute the concentration of proinflammatory substances in the tears (<a href="./references#CD011965-bbs2-0027" title="GeerlingG , TauberJ , BaudouinC , GotoE , MatsumotoY , O'BrienT , et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2011;52(4):2050‐64. ">Geerling 2011</a>). Carboxymethylcellulose and hyaluronate have been reported in the management of BKC in children (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>). Their benefit in BKC has not been supported by any trial data. </p> <p><a href="#CD011965-tbl-0002">Table 1</a> summarises the medications and outcomes used for this condition. </p> <div class="table" id="CD011965-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies of blepharokeratoconjunctivitis treatment in children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author, year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mechanical treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic (oral) interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Topical interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0012" title="Cehajic‐KapetanovicJ , KwartzJ . Augmentin duo™ in the treatment of childhood blepharokeratoconjunctivitis. Journal of Pediatric Ophthalmology and Strabismus2010;47(6):356‐60. ">Cehajic‐Kapetanovic 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin/ clavulanate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol (PF) drops, chloramphenicol ointment to lids, prednisolone 0.5% (PF)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyelid condition, corneal epitheliopathy, stromal defects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0015" title="ChoiDS , DjalilianA . Oral azithromycin combined with topical anti‐inflammatory agents in the treatment of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):112‐3. ">Choi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 months to 8 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loteprednol 0.2%, CSA 0.05%,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chalazia, keratitis, corneal ulcer/scar, phlyctenule, MGD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of itching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0020" title="DoanS , GabisonE , ChiambarettaF , TouatiM , CochereauI . Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. Journal of Ophthalmic Inflammation and Infection2013;3:38. ">Doan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 16 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin (1 participant only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 1.5%, CSA 2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bulbar conjunctival hyperaemia, conjunctival phlycten, corneal inflammation, blepharitis grade </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular irritation (redness, burning, stinging)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin suspension 450 mg divided into 3 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.5% (PF); hydrocortisone acetate 1% ointment nocte</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bulbar conjunctival redness, inferior superficial corneal vascularisation, punctate corneal epithelial staining, inferior subepithelial vascularisation and infiltrate, conjunctival phlyctenules, corneal phlyctenules, circumferential pannus, corneal scar </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Red eyes, photophobia, itching, discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal scarring and thinning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach disturbance, diarrhoea</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>615</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months to 16 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical steroids and antibiotics (not specified)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not reported (presenting signs only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not reported (presenting symptoms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 27 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azathioprine, mycophenolate mofetil, prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids (not specified)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease remission/ control of inflammation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin, doxycyclin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%, dexamethasone 0.1%, antibiotic, fluorometholone, loteprednol etabonate 0.5% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyelid inflammation, superficial punctate keratitis, corneal vascularisation, corneal infiltrates, phlyctenules, corneal scarring </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amblyopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal distress, mouth ulcers (unrelated)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months to 15.9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses, lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin, doxycyclin, flaxseed oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chloramphenicol, ciprofloxacin, gentamicin, prednisolone 1% or 0.5%, fluorometholone 0.1% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity, astigmatism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discomfort, photophobia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amblyopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal candidiasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0048" title="MeislerDM , RaizmanMB , TraboulsiEI . Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS2000;4(6):379‐80. ">Meisler 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hyperaemia and swelling, corneal infiltrates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0060" title="Rodríguez‐GarciaA , González‐GodínezS , López‐RubioS . Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome. Eye2016;30(3):438‐46. ">Rodríguez‐Garcia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.3 years (± 4.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flaxseed oil, erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lubricants (hyaluronate, methylcellulose), erythromycin, ciprofloxacin, steroids (dexamethasone 0.1% (PF), loteprednol 0.5%, fluorometholone 0.1%), CSA 0.05% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0072" title="TeoL , MehtaJS , HtoonHM , TanDT . Severity of pediatric blepharokeratoconjunctivitis in Asian eyes. American Journal of Ophthalmology2012;153(3):564‐70.e.1. ">Teo 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.2 years (± 3.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.9 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses, lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics (erythromycin, amoxicillin/ clavulanate, doxycycline), steroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids (dexamethasone 1%, prednisolone 0.12 to 1%, fluorometholone 0.1%) , antibiotics (fucidic acid, levofloxacin, tobramycin), CSA 0.5% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness, tearing, blurred vision, pain, irritation, photophobia, white spot, swelling, discharge, itching, rubbing </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raised intraocular pressure, cataract, gastrointestinal disturbance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol, steroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction of clinical signs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness, watering, itching, grittiness, discharge, photophobia, pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations:</p> <p>CSA: ciclosporin<br/> MGD: meibomian gland dysfunction<br/> N: number of participants<br/> PF: preservative‐free </p> </div> </div> </section> </section> <section id="CD011965-sec-0040"> <h3 class="title" id="CD011965-sec-0040">Why it is important to do this review</h3> <p>In paediatric eye clinics, BKC is a common and sometimes sight‐threatening condition that can affect a child’s quality of life. A Cochrane review on systemic treatment for BKC has been published (<a href="./references#CD011965-bbs2-0052" title="O'GallagherM , BantekaM , BunceC , LarkinF , TuftS , Dahlmann‐NoorA . Systemic treatment for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011750.pub2] ">O'Gallagher 2016</a>). New topical treatments with antibiotics and calcineurin inhibitors have become available. Children, their families and clinicians need accurate and unbiased data on the benefits and potential harms of the different management options available so as to inform treatment choice, particularly as medication is often required for prolonged periods of time. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011965-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011965-sec-0041"></div> <p>To assess and compare data on the efficacy and safety of topical treatments (including antibiotics, steroids, immunosuppressants and lubricants), alone or in combination, for BKC in children from birth to 16 years. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011965-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011965-sec-0042"></div> <section id="CD011965-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011965-sec-0044"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) in the review. We excluded quasi‐RCTs (e.g. those that allocated participants to treatment groups in alternating order of presentation or based on patient identification number or date of presentation). </p> </section> <section id="CD011965-sec-0045"> <h4 class="title">Types of participants</h4> <p>We included children aged zero to 16 years with a clinical diagnosis of hypersensitivity blepharokeratoconjunctivitis (BKC). </p> </section> <section id="CD011965-sec-0046"> <h4 class="title">Types of interventions</h4> <p>We evaluated topical treatments, including topical antibiotics, immunosuppressants/immunomodulators and lubricants. We included studies that evaluated a single topical medication versus placebo, a combination of treatments versus placebo, and those that compared two or multiple active treatments. We included studies in which participants received additional treatments, such as oral antibiotics, oral anti‐inflammatories, warm lid compresses and lid margin cleaning, where these were applied to both the control and intervention arms of the trial. </p> </section> <section id="CD011965-sec-0047"> <h4 class="title">Types of outcome measures</h4> <p>BKC is defined by both subjective symptoms and objective clinical changes. Improvement in symptoms is the major goal of treatment and is usually associated with a reduction in clinical signs. </p> <p>There is no validated patient‐ or parent‐/carer‐reported evaluation tool by which to quantify the symptoms of BKC. The Quality of Life in Children with Keratoconjunctivitis (QUICK) questionnaire, a tool to assess the impact of a different inflammatory eye surface condition, allergic keratoconjunctivitis, on children’s well‐being (<a href="./references#CD011965-bbs2-0062" title="SacchettiM , BaiardiniI , LambiaseA , AronniS , FassioO , GramiccioniC , et al. Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. American Journal of Ophthalmology2007;144(4):557‐63. ">Sacchetti 2007</a>), has not been evaluated in children with BKC. In adults, the Ocular Surface Disease Index (OSDI) is a commonly used symptom measure, although recently Rasch analysis has demonstrated multidimensionality and poor targeting (<a href="./references#CD011965-bbs2-0021" title="DoughertyBE , NicholsJJ , NicholsKK . Rasch analysis of the Ocular Surface Disease Index (OSDI). Investigative Ophthalmology and Visual Science2011;52(12):8630‐5. ">Dougherty 2011</a>). There is also no validated tool to measure vision‐related quality of life in children with ocular surface disorders; generic health‐related quality of life tools, such as the PedsQL (<a href="./references#CD011965-bbs2-0075" title="VarniJW , SeidM , KurtinPS . PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care2001;39(8):800‐12. ">Varni 2001</a>) or the paediatric health utility measure CHU9D (<a href="./references#CD011965-bbs2-0057" title="RatcliffeJ , CouznerL , FlynnT , SawyerM , StevensK , BrazierJ , et al. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best‐worst scaling discrete‐choice experiment, standard gamble and time trade‐off methods. Applied Health Economics and Health Policy2011;9(1):15‐27. ">Ratcliffe 2011</a>), have not been used in this context. However, as quality of life and economic outcomes are increasingly considered to be important, future work may include these or other validated measures. </p> <p>Regarding clinical signs, the grading system based on BKC activity and damage allows an evaluation of treatment efficacy (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0031" title="HamadaS , NischalK , EvansJ . The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):e16. ">Hamada 2013</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). Treatment success is reflected in a reduction of the activity score, which ranges from zero to three. Outcomes can be defined either as a change in activity score as an ordinal numerical value or, as proposed by <a href="./references#CD011965-bbs2-0031" title="HamadaS , NischalK , EvansJ . The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):e16. ">Hamada 2013</a>, as complete success (reduction in activity score to zero), partial success (exit value smaller than the baseline value) and no change (lack of treatment effect). </p> <p>A composite scoring system, such as the BKC activity/damage grading system, may overcome the problem of inconsistent reporting in clinical trials, as observed in adult meibomian gland dysfunction (MGD) trials (<a href="./references#CD011965-bbs2-0008" title="AsbellPA , StapletonFJ , WickströmK , AkpekEK , AragonaP , DanaR , et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Investigative Ophthalmology and Visual Science2011;52(4):2065‐85. ">Asbell 2011</a>; <a href="./references#CD011965-bbs2-0051" title="NicholsKK , FoulksGN , BronAJ , GlasgowBJ , DogruM , TsuhotaK , et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science2011;52(4):1922‐9. ">Nichols 2011</a>). </p> <section id="CD011965-sec-0048"> <h5 class="title">Primary outcomes</h5> <p>Percentage of children who experienced an improvement in symptoms, reported by the child or by their parents/carers, preferably measured by a validated tool, at three months (± one month) after the start of treatment. </p> </section> <section id="CD011965-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011965-list-0003"> <li> <p>Percentage of children with elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system such as those described above (<a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a>; <a href="./references#CD011965-bbs2-0031" title="HamadaS , NischalK , EvansJ . The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):e16. ">Hamada 2013</a>; <a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a>). </p> </li> <li> <p>Percentage of children with an improvement in clinical signs of ocular surface inflammation ('partial success'), preferably measured by a composite grading system as describe above. </p> </li> <li> <p>Change from baseline in best corrected visual acuity in affected eye(s) in logMAR measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at 4 m or, in younger children, with a Keeler crowded logMAR chart at 3 m. If a RCT reported visual acuity using a different chart or at a different testing distance, we considered conversion of measurements to logMAR if appropriate. </p> </li> <li> <p>Percentage of children that suffered from uncontrolled or poorly controlled disease progression due to treatment failure. </p> </li> <li> <p>Percentage of children that suffered adverse effects of medication.</p> </li> <li> <p>Adherence to treatment as measured by the percentage of study medication used (study medication issued during the course of the trial minus residual study medication returned at end of trial)/(study medication issued during the course of the trial). </p> </li> <li> <p>Total amount of topical steroids (total number of drops) used during the trial duration.</p> </li> <li> <p>Total amount of systemic immunosuppressants (total dose) used during the trial duration.</p> </li> <li> <p>Cost‐effectiveness or cost‐utility of treatments.</p> </li> <li> <p>Patient‐reported symptom severity or quality of life, measured by any validated tool.</p> </li> </ol> </p> <p>We aimed to evaluate all outcomes at three months (± two months) after the start of treatment. As disease activity and severity may differ between the two eyes of the same child (see also the '<a href="#CD011965-sec-0064">Unit of analysis issues</a>' section), we reviewed included papers to ensure that the trial included either only one eye, or, if it included both, it reported improvement for one eye or eyes separately. </p> </section> </section> </section> <section id="CD011965-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011965-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to 11 July 2016), Embase (January 1980 to 11 July 2016), the ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 11 July 2016. </p> <p>See appendices for details of search strategies for CENTRAL (<a href="./appendices#CD011965-sec-0096">Appendix 2</a>), MEDLINE (<a href="./appendices#CD011965-sec-0097">Appendix 3</a>), Embase (<a href="./appendices#CD011965-sec-0098">Appendix 4</a>), ISRCTN (<a href="./appendices#CD011965-sec-0099">Appendix 5</a>), ClinicalTrials.gov (<a href="./appendices#CD011965-sec-0100">Appendix 6</a>) and the WHO ICTRP (<a href="./appendices#CD011965-sec-0101">Appendix 7</a>). </p> <p>We modified our search strategy from the protocol when we discovered a published report of a potentially relevant trial identified in our search of ClinicalTrials.gov (<a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a>). The initial search strategy had not identified this paper due to its use of the term blepharoconjunctivitis (BC) rather than blepharokeratoconjunctivitis or blepharokeratitis. A second search of databases was carried out using the term blepharoconjunctivitis. </p> </section> <section id="CD011965-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We manually searched the reference lists of the trials included in the review for additional trials. We also used the Science Citation Index to identify reports that cited the studies included in this review. With both of these strategies we aimed to identify any other relevant reports or trials that had not been identified by the electronic searches. We did not handsearch journals or conference proceedings. </p> </section> </section> <section id="CD011965-sec-0053"> <h3 class="title" id="CD011965-sec-0053">Data collection and analysis</h3> <section id="CD011965-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the results of the search (titles and abstracts) to identify studies that loosely met the inclusion criteria of the review. Review authors were not masked with respect to study authors, institution or journal. We divided studies into 'definitely include', 'definitely exclude' and 'possibly include' categories. We made a final judgement as to the inclusion/exclusion of those in the 'possibly include' category after we obtained the full‐text copy of each article. We planned to obtain translations of relevant abstracts and, where necessary, full‐text articles into English before we made a final decision regarding inclusion/exclusion. We took care to identify multiple reports of the same study and, where identified, we linked them together. We independently examined the full‐text reports for compliance with the inclusion criteria. We resolved any disagreement over which studies to include by discussion or by consulting a third review author. We listed the studies that we excluded after we obtained the full‐text articles in a 'Characteristics of excluded studies' table and provided a reason for exclusion. Also, we created a PRISMA diagram to illustrate the study selection process. </p> </section> <section id="CD011965-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data independently using a data extraction form (<a href="./appendices#CD011965-sec-0102">Appendix 8</a>), which we developed in conjunction with Cochrane Eyes and Vision (CEV) using Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for guidance (<a href="./references#CD011965-bbs2-0034" title="HigginsJP , Deeks JJeditor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Where data were missing or unclear, one review author attempted to contact the trial authors for unpublished data or clarification. We made initial contact via email and if there was no response we sent a second email. We entered data into Review Manager (RevMan) (<a href="./references#CD011965-bbs2-0058" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>); one review author entered the data and the second review author checked for any errors. </p> <p>We aimed to collect the following information on study characteristics.</p> <p> <ol id="CD011965-list-0004"> <li> <p>Study design: parallel group RCT/one or both eyes reported.</p> </li> <li> <p>Participants: country, total number of participants, age, sex, inclusion and exclusion criteria. </p> </li> <li> <p>Intervention and comparator details: including number of people (eyes) randomised to each group. </p> </li> <li> <p>Primary and secondary outcomes as measured and reported in the trials, adverse events.</p> </li> <li> <p>Length of follow‐up.</p> </li> <li> <p>Date study conducted.</p> </li> <li> <p>Funding and conflicts of interest.</p> </li> </ol> </p> <p>We also aimed to collect the following data for our predefined outcomes separately for intervention and comparator groups. </p> <p> <ol id="CD011965-list-0005"> <li> <p>Dichotomous outcomes: number of participants followed up, number of events.</p> </li> <li> <p>Continuous outcomes: number of participants followed up, mean and standard deviation.</p> </li> </ol> </p> </section> <section id="CD011965-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias in the included studies using the Cochrane 'Risk of bias' assessment tool, detailed in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011965-bbs2-0035" title="HigginsJP , Altman DGeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>), as guidance. We graded each parameter of trial quality as either low risk of bias, high risk of bias or unclear risk of bias. </p> <p>The six main domains of the Cochrane 'Risk of bias' tool include the following.</p> <section id="CD011965-sec-0057"> <h5 class="title">Selection bias</h5> <p>We graded studies as at high risk, low risk or unclear risk based on the method of randomisation (sequence generation) and allocation concealment. Where we made an assessment of 'unclear risk' assessment, we asked the trial authors to provide further information to enable us to make a more detailed risk assessment. Examples indicative of a low risk would be randomisation using computer‐generated sequences or a random number table, the central allocation of treatments, and concealment of allocation. We classified a description of 'randomised controlled trial' without details of the allocation schedule as 'unclear', and we contacted the trial authors for more details. We classified lack of allocation concealment as 'high risk'. </p> </section> <section id="CD011965-sec-0058"> <h5 class="title">Performance bias</h5> <p>Performance bias could occur if participants/carers or staff know which treatment group the participant has been allocated to. In this review, both objective/physician‐reported outcomes and self‐report of symptoms could be affected by performance bias. We, therefore, made a judgement regarding performance bias for individual studies. </p> </section> <section id="CD011965-sec-0059"> <h5 class="title">Attrition bias</h5> <p>Attrition (e.g. following withdrawal or loss from follow‐up) can cause bias. We recorded any incomplete outcome data. We documented the rate of withdrawal from each treatment group. Where trial authors had not taken missing data into consideration, we classified the risk of bias as high. We also classified the risk of bias as high if the reason for missing outcome data was likely to be related to the true outcome, if the proportion of missing outcomes compared with observed event may have induced clinically relevant bias in intervention effect estimate (dichotomous data), if plausible effect size (difference in means or standardised difference in means) among missing outcomes may have induced clinically relevant bias in observed effect size (continuous data), if an 'as treated' analysis was performed with substantial departure of the intervention received from that assigned at randomisation, and if there was inappropriate application of simple imputation. </p> </section> <section id="CD011965-sec-0060"> <h5 class="title">Detection bias</h5> <p>We judged studies on their use of masking strategies. Detection bias can occur if outcome assessors know which treatment participants have received. </p> </section> <section id="CD011965-sec-0061"> <h5 class="title">Reporting bias</h5> <p>Where a study protocol was available, we compared the published protocol with the final outcomes to assess the risk of selective outcome reporting as high, low or unclear. If no protocol was available, we studied the full‐text article so that we could make this judgement. </p> </section> <section id="CD011965-sec-0062"> <h5 class="title">Other bias</h5> <p>We judged whether the design of each study was subject to any risk of other bias not detailed above. </p> <p>We graded the risk of bias as unclear if a publication contained insufficient information to allow a judgement to be made, and our attempts to contact the trial authors to clarify were unsuccessful. </p> <p>Review authors were not masked to any aspect of the study design and we resolved any disagreement by discussion or by consultation with a third designated review author. </p> </section> </section> <section id="CD011965-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <p>Our primary outcome was dichotomous, as were the first two secondary outcomes. The risk ratio was to be the measure of treatment effect. LogMAR visual acuity values tend to be normally distributed, and we aimed to use the mean difference as a measure of treatment effect. However, we planned to note whether or not the trial authors assessed the symmetry of their data and also how the investigate the logMAR scores, as different charts may yield different values. We aimed to use odds ratios for adverse events, but where trial reported a variety of adverse events and only one trial reported each type, we planned to simply collate this information. We also planned to collate information on adherence to treatment, simultaneous use of topical steroids and systemic immunosuppressants, and economic data. </p> </section> <section id="CD011965-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <p>Each child may have one or two affected eyes, and both disease severity and activity may differ between eyes. The topical treatment administered to the two eyes, if severity differs, may also be different. Medication administered topically can in part be absorbed systemically and have an effect on the contralateral eye, though this effect is likely to be minor. Using fellow eyes as controls would not be appropriate. </p> <p>We foresaw potential for studies to be included in which participants have one or both eyes affected. The primary outcome (i.e. whether or not the child or parent/carer reports an improvement) could be measured at the eye level or at participant level; there is, therefore, potential for a unit of analysis issue. We reviewed papers to ensure that either the trial authors included only one eye in the trial, or, if they included both eyes, they reported improvement for one eye or both eyes separately. </p> </section> <section id="CD011965-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>For each outcome we assessed whether the trial authors conducted an intention‐to‐treat analysis. One review author attempted to retrieve any missing data by contacting the authors of the relevant papers, and allowed one month for replies. Where we failed to obtain these data but the trial authors adequately examined the reasons for loss to follow‐up and found that they were similar between treatment groups, we used available‐case analyses. We documented whether the original studies stated that they compared the characteristics of participants with complete data with those of participants with no missing data and whether they provided any information about the possible effects of missing data. </p> </section> <section id="CD011965-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to examine studies for sources of methodological and clinical heterogeneity. We then planned to assess clinical, methodological and statistical heterogeneity by performing the following. </p> <p> <ol id="CD011965-list-0006"> <li> <p>We planned to look for different directions of effects and poor overlap of the confidence intervals (CIs) on the forest plot. </p> </li> <li> <p>We planned to examine the result of the Chi² test and calculation of the I² statistic with CIs. We planned to interpret the I² statistic values as advised in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011965-bbs2-0035" title="HigginsJP , Altman DGeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We did not plan to adopt strict thresholds for the I² statistic but typically would have been concerned if values were 50% or higher. </p> </li> </ol> </p> </section> <section id="CD011965-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had a sufficient number of trials (more than 10) we planned to conduct a funnel plot to assess the evidence of publication bias, although we acknowledge that asymmetry in such a plot does not always indicate publication bias. </p> </section> <section id="CD011965-sec-0068"> <h4 class="title">Data synthesis</h4> <p>We planned to perform data analyses by following the guidelines in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011965-bbs2-0018" title="DeeksJJ , HigginsJP , Altman DGeditor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>We attempted to collate all data that were relevant to our primary and secondary outcomes. If appropriate, we planned to meta‐analyse our primary outcome and the first two secondary outcomes. We foresaw potential for some studies to report composite scores for signs and symptoms, and others to report individual scores for signs and symptoms. We intended to perform meta‐analyses on the proportion of participants categorised into each of the three outcome groups based on composite scores. </p> <p>We planned to collate the results of the studies that reported only individual scores for signs and symptoms; we did not plan to include them in a meta‐analysis. </p> <p>We aimed to collate the data for other secondary outcomes, but to avoid any multiplicity issues and for review clarity, we did not plan to meta‐analyse these data but would have provided a summary in tabulated form. </p> <p>We planned to use a random‐effects model unless there was a very small number of studies (fewer than three), in which case we would have used a fixed‐effect model. If we detected substantial heterogeneity, either methodological (by review of studies) or by large values of the I² statistic (as outlined in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011965-bbs2-0035" title="HigginsJP , Altman DGeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>)), we did not plan to conduct a meta‐analysis. </p> </section> <section id="CD011965-sec-0069"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to conduct subgroup analyses based on participant age (less than eight years versus greater than or equal to eight years), as adherence to treatment may increase with age. From clinical experience, children become more understanding and allow treatment more easily from around the age of eight; also, secondary amblyopia is a risk in children under this age threshold only. </p> </section> <section id="CD011965-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct a sensitivity analysis to assess how robust our review results were to the inclusion of studies at high risk of bias (by which we mean those that we judged to be at high risk of bias in any of the 'Risk of bias' domains we assessed). </p> <section id="CD011965-sec-0071"> <h5 class="title">'Summary of findings' table</h5> <p>We planned to prepare a 'Summary of findings' table (<a href="./references#CD011965-bbs2-0035" title="HigginsJP , Altman DGeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>), describing populations, interventions and outcomes as outlined above. We did not plan to distinguish between low‐/medium‐/high‐risk populations. We have presented the proposed outline for a 'Summary of findings' table in <a href="./appendices#CD011965-sec-0103">Appendix 9</a>. We planned to use the GRADE approach (see below) to assess the certainty of the evidence and to use the GRADEpro Guideline Development Tool (GDT) to create the 'Summary of findings' table (<a href="./references#CD011965-bbs2-0028" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 14 June 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro 2014</a>). </p> <p>We have listed the GRADE Working Group grades of evidence below.</p> <p> <ul id="CD011965-list-0007"> <li> <p>High certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011965-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011965-sec-0072"></div> <section id="CD011965-sec-0073"> <h3 class="title">Description of studies</h3> <section id="CD011965-sec-0074"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a total of 440 references (<a href="#CD011965-fig-0001">Figure 1</a>). The Cochrane Information Specialist scanned the search results, removed 196 duplicates and then removed 199 references which were irrelevant to the scope of the review. We screened the remaining 45 reports and obtained seven full‐text reports for further assessment. We included two reports of one study (<a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a>), and excluded five reports of five studies (see the '<a href="./references#CD011965-sec-0112" title="">Characteristics of excluded studies</a>' table for details). </p> <div class="figure" id="CD011965-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011965-sec-0075"> <h4 class="title">Included studies</h4> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> reported a study of the use of loteprednol etabonate/tobramycin combination drop in children with BC. This was a randomised controlled trial (RCT) with four treatment arms (loteprednol etabonate/tobramycin combination, loteprednol etabonate alone, tobramycin alone or placebo). The trial randomised 137 children with BC aged zero to six years to treatment in one of the four arms for 15 days, with assessments on days 1, 3, 7 and 15. </p> </section> <section id="CD011965-sec-0076"> <h4 class="title">Excluded studies</h4> <p><a href="./references#CD011965-bbs2-0002" title="BloomPA , LeemingJP , PowerW , LaidlawDA , CollumLM , EastyDL . Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. European Journal of Ophthalmology1994;4(1):6‐12. ">Bloom 1994</a>, <a href="./references#CD011965-bbs2-0003" title="ChenM , GongL , SunX , GuY , HeX , QuJ , et al. A multicenter, randomized, parallel‐group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion2012;28(3):385‐94. ">Chen 2012</a> and <a href="./references#CD011965-bbs2-0006" title="WhiteEM , MacyJI , BatemanKM , ComstockTL . Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Current Medical Research and Opinion2008;24(1):287‐96. ">White 2008</a> were RCTs but we excluded them because they only included adult participants. </p> <p><a href="./references#CD011965-bbs2-0004" title="HosseiniK , HutchesonJ , LindstromRL . A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clinical Ophthalmology2013;7:2225‐34. ">Hosseini 2013</a> presented a RCT of azithromycin 1.0%/dexamethasone 0.1% combination drop versus azithromycin 1.0% alone or dexamethasone 0.1% alone in the treatment of BC. Of 417 participants, 19 were under 16 years of age. We contacted the study authors and their industry partners, but were unable to obtain detailed data about the paediatric subgroup, so we excluded the study. </p> <p><a href="./references#CD011965-bbs2-0005" title="ShulmanJ , KoremanN , HirshmanM , SamsonC , TrochelmanL . A double‐blind, comparative clinical trial of a new steroid, anti‐infective ophthalmic ointment for chronic staphylococcal blepharoconjunctivitis. Ocular Therapy and Surgery1982;1:192‐7. ">Shulman 1982</a> reported findings from an RCT of gentamicin‐betamethasone ointment versus gentamicin ointment alone, betamethasone ointment alone, or placebo in the treatment of acute BC. The study included people aged between 10 and 86 (N = 87). Again, we contacted the study authors, but we were unable to obtain the results for the paediatric subgroup and consequently we excluded the study. </p> <p><a href="#CD011965-tbl-0003">Table 2</a> summarises the characteristics of the two excluded studies that included children. </p> <div class="table" id="CD011965-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Randomised controlled trials of blepharokeratoconjunctivitis that included children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author, year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mechanical treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic (oral) interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Topical interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loteprednol 0.5% , tobramycin 0.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye pain, conjunctivitis, eye discharge, and eye inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0004" title="HosseiniK , HutchesonJ , LindstromRL . A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clinical Ophthalmology2013;7:2225‐34. ">Hosseini 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 417; 19 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 1%, dexamethasone 0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete bacterial eradication from conjunctiva and eyelids, complete resolution of clinical signs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete resolution of symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye disorder, reduced visual acuity, punctate keratitis, blurred vision, conjunctival oedema, discharge, lid oedema, irritation, pain, itching </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0005" title="ShulmanJ , KoremanN , HirshmanM , SamsonC , TrochelmanL . A double‐blind, comparative clinical trial of a new steroid, anti‐infective ophthalmic ointment for chronic staphylococcal blepharoconjunctivitis. Ocular Therapy and Surgery1982;1:192‐7. ">Shulman 1982</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 71; number of children not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 86 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 to 15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gentamycin 0.3%, betamethasone 0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular sign score, specific ocular inflammatory signs, bacterial eradication</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival hyperaemia</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations:</p> <p>N: number of participants <br/> RCT: randomised controlled trial </p> </div> </div> </section> </section> <section id="CD011965-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011965-fig-0002">Figure 2</a> </p> <div class="figure" id="CD011965-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011965-sec-0078"> <h4 class="title">Allocation</h4> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> used a computerised randomisation code developed by an independent statistician and we felt this represented a low risk of selection bias. </p> </section> <section id="CD011965-sec-0079"> <h4 class="title">Blinding</h4> <p>Participants in <a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> were masked to allocation and drugs were dispensed in identical containers. Due to slight differences in the consistency and appearance of the eye drops, observers were not permitted to be present during instillation of drops. We thought this represented a low risk of performance bias. The risk of detection bias was unclear. </p> </section> <section id="CD011965-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> there were some participants whose parents withdrew consent, or who were lost to follow‐up, but these were accounted for and were balanced across treatment groups. <a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> provided the safety outcome data for all participants who had received at least one dose of the intervention. We felt this represented a low risk of attrition bias. </p> </section> <section id="CD011965-sec-0081"> <h4 class="title">Selective reporting</h4> <p>The original protocol for <a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> from ClinicalTrials.gov listed the primary and secondary outcomes as change in total blepharoconjunctivitis grade at various time points. These data were not reported in the published study. The investigators have reported a mean composite blepharoconjunctivitis on clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) for each trial arm with no statistical analysis comparing groups and no details as to how they derived this grade. This represents a high risk of bias. </p> </section> <section id="CD011965-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> reported on visual acuity outcomes but the numbers of participants able to complete Snellen acuity varied from 33 to 59% across treatment groups (probably due to the age of the participants). The publication mentioned other methods of visual acuity testing but gave no account of the results of these other than 94.5% of those giving visual behaviour responses could fix and follow. We felt this represented a high risk of bias. </p> </section> </section> <section id="CD011965-sec-0083"> <h3 class="title" id="CD011965-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD011965-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> did not present any efficacy data in the published report. Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) reports blepharoconjunctivitis grade (on a scale of 0‐32) at day 3, 7 and 15 (<a href="#CD011965-tbl-0004">Table 3</a>). The registry entry contains no details on how the blepharoconjunctivitis grade was assessed. We were unable to obtain further information despite several attempts to contact the trial authors. There was little evidence of any important differences between groups. The trial authors reported visual acuity data in the publication subject to the limitations mentioned above. There was no change in visual acuity in any of the treatment groups but the presentation of the data precluded detailed analysis. </p> <div class="table" id="CD011965-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Blepharoconjunctivitis grade</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Follow‐up</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol Etabonate and Tobramycin</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol Etabonate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vehicle</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.32 (3.27) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.74 (3.90) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.94 (4.00) 32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.58 (3.46) 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.03 (3.20) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.94 (4.69) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.90 (3.80) 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.03 (4.63) 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.41 (3.29) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.23 (3.98) 35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.68 (4.71) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.30 (5.19) 33</p> </td> </tr> </tbody> </table> </div> <p>Safety data indicated that there was no statistical difference in the incidence of adverse events between treatment arms. Ocular adverse events included conjunctivitis, eye pain, discharge and inflammation. Non‐ocular adverse events reported were ear infection, ear pain, otitis media, diarrhoea, gastroenteritis, lip swelling, vomiting, pyrexia, urticaria, bronchiolitis, upper respiratory infection, nasopharyngitis, tonsillitis, varicella, dehydration, cough, pharyngolaryngeal pain, respiratory distress, dermatitis and rash. There were no ocular serious adverse events and the authors considered it unlikely for most of the adverse events to be due to treatment. Data for ocular adverse events included any treated fellow eyes, which made further analysis difficult. <a href="#CD011965-tbl-0005">Table 4</a> summarises the adverse events seen in each study group. </p> <div class="table" id="CD011965-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events seen in each study group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol/tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vehicle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/34 (eye pain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/35 (eye pain, conjunctivitis, eye discharge, eye inflammation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐Ocular AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/34 3 AEs (gastroenteritis, pyrexia, bronchiolitis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/35 9 AEs (ear infection, lip swelling, vomiting, URI, varicella, cough, phyarngolaryngeal pain, rash) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/34 9 AEs (ear infection, otitis media acute, diarrhea, pyrexia, bronchioltis, URI, nasophayngitis, respirator distress, dermatitis (diaper) ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/33 7 AEs (ear pain, pyrexia, urticaria, bronchioloitis, URI, tonsilitis, dehydration)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations:</p> <p>AEs: adverse events</p> </div> </div> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011965-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011965-sec-0084"></div> <section id="CD011965-sec-0085"> <h3 class="title" id="CD011965-sec-0085">Summary of main results</h3> <p>Only one of the included publications presented sufficient data on children that we could include in this review. It presented data on adverse events only, and did not present sufficient data on improvement in symptoms or signs. The authors presented visual acuity data in a form that precluded extraction for use in this review but they reported no statistically significant changes in visual acuity with either treatment or placebo. There was no difference in adverse events with treatments compared to placebo but it is unclear if this trial was designed with appropriate statistical power to detect a difference. </p> </section> <section id="CD011965-sec-0086"> <h3 class="title" id="CD011965-sec-0086">Overall completeness and applicability of evidence</h3> <p>While we identified three randomised controlled trials (RCTs) with paediatric participants, two trials pertained to mixed participant groups of adults and children, and did not clearly match the definition of blepharokeratoconjunctivitis (BKC). The third trial, <a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a>, reported primarily on adverse effects and did not report completely on changes in symptoms and signs. Treatment was limited to two weeks in duration. No RCTs on long‐term treatments met the inclusion criteria of this review. </p> <p>The treatment in the included study consisted of topical corticosteroid and antibiotic drops, both of which are used in clinical practice as noted in the <a href="#CD011965-sec-0028">Description of the intervention</a> section. The duration of treatment is short in comparison to the long term nature of this condition (<a href="#CD011965-sec-0024">Description of the condition</a>). </p> </section> <section id="CD011965-sec-0087"> <h3 class="title" id="CD011965-sec-0087">Quality of the evidence</h3> <p>One RCT including 137 participants met the inclusion criteria of this review. Although the randomisation of participants was rigorous, we have identified some risk of bias in this trial. We do not have a large body of high quality evidence to support our conclusions. </p> </section> <section id="CD011965-sec-0088"> <h3 class="title" id="CD011965-sec-0088">Potential biases in the review process</h3> <p>Our approach to this review was based on a broad search, and we included any reports on this condition. We amended and broadened our search strategy further when it became apparent that we might have missed a potentially relevant study. With the enhanced strategy it is less likely that the search would have overlooked any relevant studies. The review authors reviewed the results independently, thus eliminating selection bias. We sought to obtain all relevant data from authors where it was not available in published reports but we were not successful leading to potential omission of relevant data. </p> </section> <section id="CD011965-sec-0089"> <h3 class="title" id="CD011965-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>We are unaware of any other systematic review of high‐quality evidence that has been undertaken on this topic. There are some narrative reviews about BKC and its treatment, but they have neither followed systematic review methodology nor assessed the quality of evidence (<a href="./references#CD011965-bbs2-0033" title="HammersmithKM . Blepharokeratoconjunctivitis in children. Current Opinion in Ophthalmology2015;26(4):301‐5. ">Hammersmith 2015</a>, <a href="./references#CD011965-bbs2-0078" title="WongIB , NischalKK . Managing a child with an external ocular disease. Journal of AAPOS2010;14(1):68‐77. ">Wong 2010</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011965-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/urn:x-wiley:14651858:media:CD011965:CD011965-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_t/tCD011965-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011965-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/urn:x-wiley:14651858:media:CD011965:CD011965-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_t/tCD011965-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/media/CDSR/CD011965/image_n/nCD011965-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011965-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical treatments compared with control for blepharokeratoconjunctivitis in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with blepharokeratoconjunctivitis </p> <p><b>Settings:</b> eye clinic </p> <p><b>Intervention:</b> topical treatments (antibiotics and/or steroids) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo (vehicle)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>topical treatments (antibiotics/steroids)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms, reported by the child or by their parents/carers, preferably measured by a validated tool, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on changes in grade of blepharoconjunctivitis measured between baseline and 2 weeks did not suggest any important differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of clinical signs of ocular surface inflammation ('partial success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on changes in grade of blepharoconjunctivitis measured between baseline and 2 weeks did not suggest any important differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in best corrected visual acuity in affected eye(s) in logMAR measured with an ETDRS chart at 4 m, or, in younger children, with a Keeler crowded logMAR chart at 3 m, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data in a form that could not be extracted; not statistically significant differences between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of medication, at any time during treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Ocular adverse events</p> <p> <ul id="CD011965-list-0001"> <li> <p>Loteprednol/tobramycin 1/34 (eye pain)</p> </li> <li> <p>Loteprednol 4/35 (eye pain, conjunctivitis, eye discharge, eye inflammation)</p> </li> <li> <p>Tobramycin 0/34</p> </li> <li> <p>Vehicle 0/34</p> </li> </ul> </p> <p>Non‐ocular adverse events</p> <p> <ul id="CD011965-list-0002"> <li> <p>Loteprednol/tobramycin 3 in 2/34 people (gastroenteritis, pyrexia, bronchiolitis)</p> </li> <li> <p>Loteprednol 9 in 6/35 people (ear infection, lip swelling, vomiting, URI, varicella, cough, phyarngolaryngeal pain, rash) </p> </li> <li> <p>Tobramycin 9 in 6/34 people (ear infection, otitis media acute, diarrhea, pyrexia, bronchioltis, URI, nasophayngitis, respirator distress, dermatitis (diaper) ) </p> </li> <li> <p>Vehicle 7 in 5/33 people (ear pain, pyrexia, urticaria, bronchioloitis, URI, tonsilitis, dehydration) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Some data on blepharoconjunctivitis grade reported on trials registry but we were unable to estimate a measure of effect for this outcome. </p> <p>2 Data were not fully reported and we were unable to estimate a measure of effect for change in visual acuity. </p> <p>3 Very low certainty due to very low numbers of events.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011965-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies of blepharokeratoconjunctivitis treatment in children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author, year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mechanical treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic (oral) interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Topical interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0012" title="Cehajic‐KapetanovicJ , KwartzJ . Augmentin duo™ in the treatment of childhood blepharokeratoconjunctivitis. Journal of Pediatric Ophthalmology and Strabismus2010;47(6):356‐60. ">Cehajic‐Kapetanovic 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxicillin/ clavulanate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol (PF) drops, chloramphenicol ointment to lids, prednisolone 0.5% (PF)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyelid condition, corneal epitheliopathy, stromal defects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0015" title="ChoiDS , DjalilianA . Oral azithromycin combined with topical anti‐inflammatory agents in the treatment of blepharokeratoconjunctivitis in children. Journal of AAPOS2013;17(1):112‐3. ">Choi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 months to 8 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loteprednol 0.2%, CSA 0.05%,</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chalazia, keratitis, corneal ulcer/scar, phlyctenule, MGD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement of itching</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0020" title="DoanS , GabisonE , ChiambarettaF , TouatiM , CochereauI . Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis. Journal of Ophthalmic Inflammation and Infection2013;3:38. ">Doan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 16 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Variable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin (1 participant only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 1.5%, CSA 2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bulbar conjunctival hyperaemia, conjunctival phlycten, corneal inflammation, blepharitis grade </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular irritation (redness, burning, stinging)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0025" title="FarpourB , McClellanKA . Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus2001;38(4):207‐12. ">Farpour 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin suspension 450 mg divided into 3 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.5% (PF); hydrocortisone acetate 1% ointment nocte</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bulbar conjunctival redness, inferior superficial corneal vascularisation, punctate corneal epithelial staining, inferior subepithelial vascularisation and infiltrate, conjunctival phlyctenules, corneal phlyctenules, circumferential pannus, corneal scar </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Red eyes, photophobia, itching, discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal scarring and thinning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach disturbance, diarrhoea</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0029" title="GuptaN , DhawanA , BeriS , D'SouzaP . Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS2010;14(6):527‐9. ">Gupta 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>615</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months to 16 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical steroids and antibiotics (not specified)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not reported (presenting signs only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes not reported (presenting symptoms only)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0030" title="HamadaS , KhanI , DennistonAK , RauzS . Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology2012;96(7):949‐55. ">Hamada 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 27 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azathioprine, mycophenolate mofetil, prednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids (not specified)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease remission/ control of inflammation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>none</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0032" title="HammersmithKM , CohenEJ , BlakeTD , LaibsonPR , RapuanoCJ . Blepharokeratoconjunctivitis in children. Archives of Ophthalmology2005;123(12):1667‐70. ">Hammersmith 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin, doxycyclin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 1%, dexamethasone 0.1%, antibiotic, fluorometholone, loteprednol etabonate 0.5% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyelid inflammation, superficial punctate keratitis, corneal vascularisation, corneal infiltrates, phlyctenules, corneal scarring </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amblyopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal distress, mouth ulcers (unrelated)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0037" title="JonesSM , WeinsteinJM , CumberlandP , KleinN , NischalKK . Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology2007;114(12):2271‐80. ">Jones 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months to 15.9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses, lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin, doxycyclin, flaxseed oil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>chloramphenicol, ciprofloxacin, gentamicin, prednisolone 1% or 0.5%, fluorometholone 0.1% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity, astigmatism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discomfort, photophobia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amblyopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaginal candidiasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0048" title="MeislerDM , RaizmanMB , TraboulsiEI . Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS2000;4(6):379‐80. ">Meisler 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hyperaemia and swelling, corneal infiltrates</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0060" title="Rodríguez‐GarciaA , González‐GodínezS , López‐RubioS . Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome. Eye2016;30(3):438‐46. ">Rodríguez‐Garcia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 9.3 years (± 4.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flaxseed oil, erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lubricants (hyaluronate, methylcellulose), erythromycin, ciprofloxacin, steroids (dexamethasone 0.1% (PF), loteprednol 0.5%, fluorometholone 0.1%), CSA 0.05% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0072" title="TeoL , MehtaJS , HtoonHM , TanDT . Severity of pediatric blepharokeratoconjunctivitis in Asian eyes. American Journal of Ophthalmology2012;153(3):564‐70.e.1. ">Teo 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.2 years (± 3.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.9 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Warm compresses, lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics (erythromycin, amoxicillin/ clavulanate, doxycycline), steroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steroids (dexamethasone 1%, prednisolone 0.12 to 1%, fluorometholone 0.1%) , antibiotics (fucidic acid, levofloxacin, tobramycin), CSA 0.5% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness, tearing, blurred vision, pain, irritation, photophobia, white spot, swelling, discharge, itching, rubbing </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corneal perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Raised intraocular pressure, cataract, gastrointestinal disturbance</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0076" title="ViswalingamM , RauzS , MorletN , DartJK . Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology2005;89(4):400‐3. ">Viswalingam 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lid hygiene</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol, steroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction of clinical signs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness, watering, itching, grittiness, discharge, photophobia, pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>Abbreviations:</p> <p>CSA: ciclosporin<br/> MGD: meibomian gland dysfunction<br/> N: number of participants<br/> PF: preservative‐free </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies of blepharokeratoconjunctivitis treatment in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011965-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Randomised controlled trials of blepharokeratoconjunctivitis that included children</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author, year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean/median follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mechanical treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic (oral) interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Topical interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physician‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient‐reported outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events from treatment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0001" title="ComstockTL , PaternoMR , BatemanKM , DeCoryHH , GearingerM . Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric Drugs2012;14(2):119‐30. ">Comstock 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loteprednol 0.5% , tobramycin 0.3%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual acuity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye pain, conjunctivitis, eye discharge, and eye inflammation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0004" title="HosseiniK , HutchesonJ , LindstromRL . A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clinical Ophthalmology2013;7:2225‐34. ">Hosseini 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 417; 19 children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 1%, dexamethasone 0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete bacterial eradication from conjunctiva and eyelids, complete resolution of clinical signs </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complete resolution of symptoms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye disorder, reduced visual acuity, punctate keratitis, blurred vision, conjunctival oedema, discharge, lid oedema, irritation, pain, itching </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011965-bbs2-0005" title="ShulmanJ , KoremanN , HirshmanM , SamsonC , TrochelmanL . A double‐blind, comparative clinical trial of a new steroid, anti‐infective ophthalmic ointment for chronic staphylococcal blepharoconjunctivitis. Ocular Therapy and Surgery1982;1:192‐7. ">Shulman 1982</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 71; number of children not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 86 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 to 15 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gentamycin 0.3%, betamethasone 0.1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocular sign score, specific ocular inflammatory signs, bacterial eradication</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival hyperaemia</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>Abbreviations:</p> <p>N: number of participants <br/> RCT: randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Randomised controlled trials of blepharokeratoconjunctivitis that included children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011965-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Blepharoconjunctivitis grade</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Follow‐up</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol Etabonate and Tobramycin</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol Etabonate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vehicle</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.32 (3.27) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.74 (3.90) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.94 (4.00) 32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.58 (3.46) 31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.03 (3.20) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.94 (4.69) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.90 (3.80) 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.03 (4.63) 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.41 (3.29) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.23 (3.98) 35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.68 (4.71) 34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10.30 (5.19) 33</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Blepharoconjunctivitis grade</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011965-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events seen in each study group</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol/tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loteprednol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vehicle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/34 (eye pain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/35 (eye pain, conjunctivitis, eye discharge, eye inflammation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐Ocular AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/34 3 AEs (gastroenteritis, pyrexia, bronchiolitis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/35 9 AEs (ear infection, lip swelling, vomiting, URI, varicella, cough, phyarngolaryngeal pain, rash) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/34 9 AEs (ear infection, otitis media acute, diarrhea, pyrexia, bronchioltis, URI, nasophayngitis, respirator distress, dermatitis (diaper) ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/33 7 AEs (ear pain, pyrexia, urticaria, bronchioloitis, URI, tonsilitis, dehydration)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Abbreviations:</p> <p>AEs: adverse events</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events seen in each study group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011965.pub2/full#CD011965-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011965.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011965-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011965-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD011965-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011965-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011965\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011965\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011965\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011965\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011965.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011965.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011965.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011965.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011965.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720012381"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011965.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720012385"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011965.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df6c788559368',t:'MTc0MDcyMDAxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 